公开(公告)号：US10745462B2

公开(公告)日：2020-08-18

申请号：US16393277

申请日：2019-04-24

Applicant: Acceleron Pharma Inc.

Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne S. Sako ,  Roselyne Castonguay ,  Rita Steeves

IPC: A61K38/00 ,  C07K14/71 ,  C07K14/495 ,  C07K16/22

Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of TβRII polypeptide useful to selectively antagonize a TβRII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGFβ associated disorders.

公开(公告)号：US20200087367A1

公开(公告)日：2020-03-19

申请号：US16482883

申请日：2018-02-05

Applicant: Acceleron Pharma Inc.

Inventor： Gang Li ,  Asya Grinberg ,  Dianne Sako

IPC: C07K14/51 ,  C07K14/71 ,  C07K14/705 ,  C07K16/22 ,  A61P9/04

Abstract: In certain aspects, the present disclosure relates to methods of treating, preventing, and reducing the severity or progression of heart failure or one or more complications of heart failure. For example, the disclosure provides various BMP antagonists, such as ActRIIA polypeptides, ActRIIB polypeptides, BMPRII polypeptides, ALKI polypeptides, endoglin polypeptides, BMP 10 propeptide proteins and Fc fusion proteins thereof as well as anti-BMP9 antibodies, for treating, preventing and reducing the severity or progression of heart failure or one or more complications of heart failure.

公开(公告)号：US20190284257A1

公开(公告)日：2019-09-19

申请号：US16393277

申请日：2019-04-24

Applicant: Acceleron Pharma Inc.

Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne S. Sako ,  Roselyne Castonguay ,  Rita Steeves

IPC: C07K14/71 ,  C07K16/22 ,  C07K14/495

Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of TβRII polypeptide useful to selectively antagonize a TβRII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGFβ associated disorders.

公开(公告)号：US20190225669A1

公开(公告)日：2019-07-25

申请号：US16251325

申请日：2019-01-18

Applicant: Acceleron Pharma Inc.

Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne Sako ,  Robert Scott Pearsall ,  Roselyne Castonguay

IPC: C07K14/71 ,  C12N9/12 ,  A61K38/45

Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells. In certain aspects, such soluble polypeptide complexes are can be used to improve muscle formation, bone formation, hematopoiesis, metabolic parameters, and disorders associated with these tissues, cellular networks, and endocrine systems.

公开(公告)号：US10316076B2

公开(公告)日：2019-06-11

申请号：US15714015

申请日：2017-09-25

Applicant: Acceleron Pharma Inc.

Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne S. Sako ,  Roselyne Castonguay ,  Rita Steeves

IPC: C07K14/71 ,  C07K14/495 ,  C07K16/22 ,  A61K38/00

Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of TβRII polypeptide useful to selectively antagonize a TβRII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGFβ associated disorders.

公开(公告)号：US10307455B2

公开(公告)日：2019-06-04

申请号：US15456392

申请日：2017-03-10

Applicant: Acceleron Pharma Inc. ,  Adimab, LLC

Inventor： Ravindra Kumar ,  Jonathan Belk ,  Asya Grinberg ,  Dianne Sako ,  Roselyne Castonguay

IPC: C07K14/00 ,  C07K14/47 ,  A61K38/00 ,  A61K38/02 ,  A61K38/16 ,  A61K39/395 ,  C07K5/00

Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.

公开(公告)号：US20190100570A1

公开(公告)日：2019-04-04

申请号：US16158661

申请日：2018-10-12

Applicant: Acceleron Pharma Inc.

Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne Sako ,  Robert Scott Pearsall ,  Roselyne Castonguay

IPC: C07K14/705 ,  C07K14/71

Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.

公开(公告)号：US10227393B2

公开(公告)日：2019-03-12

申请号：US15092609

申请日：2016-04-06

Applicant: Acceleron Pharma Inc.

Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne Sako ,  Robert Scott Pearsall ,  Roselyne Castonguay

IPC: C07K14/71 ,  A61K38/00 ,  A61K38/45 ,  C12N9/12

Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells. In certain aspects, such soluble polypeptide complexes are can be used to improve muscle formation, bone formation, hematopoiesis, metabolic parameters, and disorders associated with these tissues, cellular networks, and endocrine systems.

公开(公告)号：US20190023797A1

公开(公告)日：2019-01-24

申请号：US16054446

申请日：2018-08-03

Applicant: Acceleron Pharma Inc. ,  Dyax Corp.

Inventor： Ravindra Kumar ,  Asya Grinberg ,  Monique Davies ,  Diana Martik ,  Janja Cosic ,  Rachel Kent ,  David Buckler

IPC: C07K16/28 ,  C07K16/40

Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.

公开(公告)号：US20180305427A1

公开(公告)日：2018-10-25

申请号：US15957026

申请日：2018-04-19

Applicant: Acceleron Pharma Inc.

Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne S. Sako

IPC: C07K14/47 ,  C07K19/00 ,  A61K47/68 ,  A61K38/00

CPC classification number: C07K14/4703 ,  A61K38/00 ,  A61K47/6811 ,  C07K14/4702 ,  C07K19/00 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/74

Abstract: In certain aspects, the present disclosure provides compositions and methods for inhibiting activity of TGFβ superfamily ligands, particularly ligands such as GDF8, GDF11, activin A, activin B, activin C and activin E, in vertebrates, including rodents and primates, and particularly in humans. In some embodiments, the compositions of the disclosure may be used to treat or prevent diseases or disorders that are associated with abnormal activity of a follistatin-related polypeptide and/or a follistatin ligand.